Carol L Shields1, Swathi Kaliki2, Minoru Furuta2, Enzo Fulco2, Carolina Alarcon2, Jerry A Shields2. 1. Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania. Electronic address: carol.shields@shieldsoncology.com. 2. Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
Abstract
PURPOSE: To analyze the clinical features and prognosis of posterior uveal melanoma based on the American Joint Committee on Cancer (AJCC) (7th edition) tumor staging. DESIGN: Retrospective interventional case series. PARTICIPANTS: A total of 7731 patients. METHODS: Uveal melanoma management. MAIN OUTCOME MEASURES: Melanoma-related metastasis and death. RESULTS: Of 7731 patients with posterior uveal (ciliary body and choroidal) melanoma, the AJCC tumor staging was stage I in 2767 (36%), stage II in 3735 (48%), stage III in 1220 (16%), and stage IV in 9 (<1%). Based on tumor staging (I, II, III, and IV), features that showed significant increase with tumor staging included age at presentation (57, 58, 60, 60 years) (P < 0.001), tumor base (8, 12, 17, 17 mm) (P < 0.001), tumor thickness (2.9, 6.0, 10.1, 10.2 mm) (P < 0.001), distance to optic disc (3, 5, 5, 5 mm) (P < 0.001), distance to foveola (3, 5, 5, 5 mm) (P < 0.001), mushroom configuration (6%, 24%, 34%, 33%) (P < 0.001), plateau configuration (3%, 4%, 7%, 11%) (P < 0.001), tumor pigmentation (48%, 53%, 69%, 78%) (P < 0.001), and extraocular extension (0%, 1%, 11%, 22%) (P < 0.001). After therapy, Kaplan-Meier estimates of metastasis at 1, 5, 10, and 20 years were <1%, 5%, 12%, and 20% for stage I, 2%; 17%, 29%, and 44% for stage II; 6%, 44%, 61%, and 73% for stage III, and 100% by 1 year for stage IV. Kaplan-Meier estimates of death at 1, 5, 10, and 20 years were <1%, 3%, 6%, and 8% for stage I; <1%, 9%, 15%, and 24% for stage II; 3%, 27%, 39%, and 53% for stage III, and 100% by 1 year for stage IV. Compared with stage I, the hazard ratio for metastasis/death was 3.1/3.1 for stage II and 9.3/10.1 for stage III. CONCLUSIONS: Compared with uveal melanoma classified as AJCC stage I, the rate of metastasis/death was 3 times greater for stage II, 9 to 10 times greater for stage III, and further greater for stage IV. Early detection of posterior uveal melanoma, at a point when the tumor is small, can be lifesaving.
PURPOSE: To analyze the clinical features and prognosis of posterior uveal melanoma based on the American Joint Committee on Cancer (AJCC) (7th edition) tumor staging. DESIGN: Retrospective interventional case series. PARTICIPANTS: A total of 7731 patients. METHODS:Uveal melanoma management. MAIN OUTCOME MEASURES: Melanoma-related metastasis and death. RESULTS: Of 7731 patients with posterior uveal (ciliary body and choroidal) melanoma, the AJCC tumor staging was stage I in 2767 (36%), stage II in 3735 (48%), stage III in 1220 (16%), and stage IV in 9 (<1%). Based on tumor staging (I, II, III, and IV), features that showed significant increase with tumor staging included age at presentation (57, 58, 60, 60 years) (P < 0.001), tumor base (8, 12, 17, 17 mm) (P < 0.001), tumor thickness (2.9, 6.0, 10.1, 10.2 mm) (P < 0.001), distance to optic disc (3, 5, 5, 5 mm) (P < 0.001), distance to foveola (3, 5, 5, 5 mm) (P < 0.001), mushroom configuration (6%, 24%, 34%, 33%) (P < 0.001), plateau configuration (3%, 4%, 7%, 11%) (P < 0.001), tumor pigmentation (48%, 53%, 69%, 78%) (P < 0.001), and extraocular extension (0%, 1%, 11%, 22%) (P < 0.001). After therapy, Kaplan-Meier estimates of metastasis at 1, 5, 10, and 20 years were <1%, 5%, 12%, and 20% for stage I, 2%; 17%, 29%, and 44% for stage II; 6%, 44%, 61%, and 73% for stage III, and 100% by 1 year for stage IV. Kaplan-Meier estimates of death at 1, 5, 10, and 20 years were <1%, 3%, 6%, and 8% for stage I; <1%, 9%, 15%, and 24% for stage II; 3%, 27%, 39%, and 53% for stage III, and 100% by 1 year for stage IV. Compared with stage I, the hazard ratio for metastasis/death was 3.1/3.1 for stage II and 9.3/10.1 for stage III. CONCLUSIONS: Compared with uveal melanoma classified as AJCC stage I, the rate of metastasis/death was 3 times greater for stage II, 9 to 10 times greater for stage III, and further greater for stage IV. Early detection of posterior uveal melanoma, at a point when the tumor is small, can be lifesaving.
Authors: Brandon T Nguyen; Ryan S Kim; Maria E Bretana; Eric Kegley; Amy C Schefler Journal: Graefes Arch Clin Exp Ophthalmol Date: 2017-11-28 Impact factor: 3.117
Authors: Duncan E Berry; Amy C Schefler; Michael I Seider; Miguel Materin; Sandra Stinnett; Prithvi Mruthyunjaya Journal: Retina Date: 2018-11-08 Impact factor: 4.256
Authors: Albert Liao; Pardeep Mittal; David H Lawson; Jenny J Yang; Eszter Szalai; Hans E Grossniklaus Journal: Ophthalmology Date: 2017-11-06 Impact factor: 12.079
Authors: Eric Londin; Rogan Magee; Carol L Shields; Sara E Lally; Takami Sato; Isidore Rigoutsos Journal: Pigment Cell Melanoma Res Date: 2019-08-16 Impact factor: 4.693
Authors: Rhonda C Kines; Isabella Varsavsky; Sanghamitra Choudhary; Debaditya Bhattacharya; Sean Spring; Roger McLaughlin; Shin J Kang; Hans E Grossniklaus; Demetrios Vavvas; Stephen Monks; John R MacDougall; Elisabet de Los Pinos; John T Schiller Journal: Mol Cancer Ther Date: 2017-12-14 Impact factor: 6.261
Authors: Carol L Shields; Lauren A Dalvin; Michael Chang; Mehdi Mazloumi; Patricia Fortin; Mark McGarrey; Andrei Martin; Antonio Yaghy; Xiaolu Yang; Pornpattana Vichitvejpaisal; Arman Mashayekhi; Jerry A Shields Journal: JAMA Ophthalmol Date: 2020-02-01 Impact factor: 7.389